daclizumab high-yield (dac hyp  (Biogen Inc)

Journal: Biomedicines

Article Title: Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

doi: 10.3390/biomedicines7010018

Figure Lengend Snippet: Selected Clinical and MRI Outcomes of DAC HYP Treatment in RMS Controlled Trials.

Article Snippet: Subcutaneous DAC, often referred to as DAC High Yield Process (DAC HYP; Zinbryta, Biogen, Cambridge MA and AbbVie, Chicago II), demonstrated efficacy in reducing both clinical and MRI measures of disease activity in patients with relapsing forms of multiple sclerosis (RMS) and was approved to treat RMS in 2016 [ , , , ].

Techniques: Selection

Journal: Biomedicines

Article Title: Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

doi: 10.3390/biomedicines7010018

Figure Lengend Snippet: Adverse Event Incidence for DAC treated patients in Controlled Trials of DAC HYP.

Article Snippet: Subcutaneous DAC, often referred to as DAC High Yield Process (DAC HYP; Zinbryta, Biogen, Cambridge MA and AbbVie, Chicago II), demonstrated efficacy in reducing both clinical and MRI measures of disease activity in patients with relapsing forms of multiple sclerosis (RMS) and was approved to treat RMS in 2016 [ , , , ].

Techniques: Selection, Infection

Journal: Biomedicines

Article Title: Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

doi: 10.3390/biomedicines7010018

Figure Lengend Snippet: Cutaneous AE Incidence for DAC treated patients in Controlled Trials of DAC HYP.

Article Snippet: Subcutaneous DAC, often referred to as DAC High Yield Process (DAC HYP; Zinbryta, Biogen, Cambridge MA and AbbVie, Chicago II), demonstrated efficacy in reducing both clinical and MRI measures of disease activity in patients with relapsing forms of multiple sclerosis (RMS) and was approved to treat RMS in 2016 [ , , , ].

Techniques: Selection

Journal: Therapeutic Advances in Neurological Disorders

Article Title: Daclizumab high-yield process in the treatment of relapsing–remitting multiple sclerosis

doi: 10.1177/1756285616671887

Figure Lengend Snippet: Table 1.

Article Snippet: The DECIDE study [ ClinicalTrials.gov identifier: {"type":"clinical-trial","attrs":{"text":"NCT01064401","term_id":"NCT01064401"}} NCT01064401 ] is an international phase III, randomized, double-blind clinical trial of 96 weeks of monotherapy with DAC HYP 150 mg versus interferon β 1a (Avonex, Biogen, Cambridge, MA, USA) in MS. A total of 1841 patients enrolled in the study had relapsing MS with a mean duration of symptoms of almost 7 years [standard deviation (SD) 6.3], mean EDSS score of 2.5, an ARR of 12 months prior to the baseline 1.5 (SD 0.7) and were randomized in the double dummy design to weekly administration of 30 mg of intramuscular interferon β 1a ( n = 922) or 150 mg of DAC HYP ( n = 919) administered subcutaneously every 4 weeks.

Techniques: Clinical Proteomics